Nanoligent

Nanoligent company information, Employees & Contact Information

Explore related pages

Related company profiles:

Our mision is to improve the life of patients by designing new medicines that selectively target the cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs. We design our new drugs using state-of-the-art protein engineering and nanobiotechnology. First Project: New anti-metastatic drug Since cancer is the second cause of death worlwide, there is an urgent need for more effective and personalized treatments of tumors. Metastasis development is the main cause of patient death in most tumor types but the control of metastasis in cancer is still an unmet medical need. The current surgery-based approaches and conventional chemotherapy can be enhanced using new technologies. Our first project is a self-assembling protein nanoparticle that selectively kills metastatic cells. This nanoconjugate targets CXCR4 receptors which are over-expressed in metastatic cells of many types of cáncer. Preclinical results look very promising: in vivo results show that our drug-loaded nanoconjugate accumulates in primary tumor and metastatic foci with negible presence in liver, kidney, brain or other organs. The result is a significant decrease of the number of metastatic foci and very low toxicity on normal cells. Our focus now is to complete preclinical development in order to obtain approval for first-in-human trial.

Company Details

Employees
13
Address
Edificio Eureka Av. De Can Doménech S/n Campus De La Uab, Bellaterra,barcelona 08193,spain
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
IT Consulting.
HQ
Bellaterra, Barcelona
Looking for a particular Nanoligent employee's phone or email?

Nanoligent Questions

News

Nanoligent raised €2.8M and completed Seed round financing with support of i&i Biotech Fund I - uab.cat

Nanoligent raised €2.8M and completed Seed round financing with support of i&i Biotech Fund I uab.cat

Barcelona-based Nanoligent raises €12M to fight cancer with precision nanodrugs - Silicon Canals

Barcelona-based Nanoligent raises €12M to fight cancer with precision nanodrugs Silicon Canals

Nanoligent and BrainMapp win Santander X Award at UAB - uab.cat

Nanoligent and BrainMapp win Santander X Award at UAB uab.cat

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant